• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Recombinant human interleukin 4 (IL-4) given as daily subcutaneous injections--a phase I dose toxicity trial.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Gilleece, Maria H
    Scarffe, J Howard
    Ghosh, Anna K
    Heyworth, Clare M
    Bonnem, E
    Testa, Nydia G
    Stern, Peter L
    Dexter, T Michael
    Affiliation
    Cancer Research Campaign, Department of Experimental Haematology, Christie Hospital NHS Trust, Manchester, U.K.
    Issue Date
    1992-07
    
    Metadata
    Show full item record
    Abstract
    Recombinant Interleukin 4 was administered by subcutaneous injection at daily doses of 0.5, 1.0 or 5.0 micrograms kg-1 to nine patients as part of a Phase I Dose Toxicity Study. Dose limiting toxicity was reached at 5 micrograms kg-1 day-1. Symptoms of toxicity included fatigue, 'flu like symptoms and elevated liver enzymes. Modest but significant elevations of neutrophil and platelet counts occurred. No clear evidence of antitumour effects emerged although pain in metastatic lymph nodes and a small fall in myeloma paraprotein levels during dosing were observed. In vitro and murine in vivo studies indicate that patients with lymphoproliferative disease should be selected for Phase II trials.
    Citation
    Recombinant human interleukin 4 (IL-4) given as daily subcutaneous injections--a phase I dose toxicity trial. 1992, 66 (1):204-10 Br. J. Cancer
    Journal
    British Journal of Cancer
    URI
    http://hdl.handle.net/10541/109648
    PubMed ID
    1637669
    Type
    Article
    Language
    en
    ISSN
    0007-0920
    Collections
    All Christie Publications
    All Paterson Institute for Cancer Research

    entitlement

    Related articles

    • Phase I trial of subcutaneous interleukin-6 in patients with advanced malignancies.
    • Authors: Weber J, Yang JC, Topalian SL, Parkinson DR, Schwartzentruber DS, Ettinghausen SE, Gunn H, Mixon A, Kim H, Cole D
    • Issue date: 1993 Mar
    • Safety evaluation of recombinant human interleukin-4. II. Clinical studies.
    • Authors: Leach MW, Rybak ME, Rosenblum IY
    • Issue date: 1997 Apr
    • Phase I study of intravenously administered bacterially synthesized granulocyte-macrophage colony-stimulating factor and comparison with subcutaneous administration.
    • Authors: Lieschke GJ, Maher D, O'Connor M, Green M, Sheridan W, Rallings M, Bonnem E, Burgess AW, McGrath K, Fox RM
    • Issue date: 1990 Feb 1
    • Biologic effects of recombinant human interleukin-3 in vivo.
    • Authors: Lindemann A, Ganser A, Herrmann F, Frisch J, Seipelt G, Schulz G, Hoelzer D, Mertelsmann R
    • Issue date: 1991 Dec
    • Phase I trial of recombinant human macrophage colony-stimulating factor administered by continuous intravenous infusion in patients with metastatic cancer.
    • Authors: Cole DJ, Sanda MG, Yang JC, Schwartzentruber DJ, Weber J, Ettinghausen SE, Pockaj BA, Kim HI, Levin RD, Pogrebniak HW
    • Issue date: 1994 Jan 5
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.